BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric ...
BOSTON, July 10, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing Phase 1/2 study of PTR-01 (BBP-589), an intravenously- …